Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Hagop M. Kantarjian, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D. Le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, Hanna Jean Khoury, Moshe Talpaz, John F DiPersio, Michele Baccarani, Stephanie Lustgarten, Frank G. Haluska, Francois Guilhot, Michael W.N. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Jorge E. Cortes
Institutions: The University of Texas MD Anderson Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Moffitt Cancer Center, Charité - Universitätsmedizin Berlin, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Singapore General Hospital, Duke-NUS Medical School, Hôpital Lyon Sud, Imperial College London, Winship Cancer Institute, University of Michigan, Washington University in St. Louis, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, ARIAD Pharmaceuticals (United States), Centre Hospitalier Universitaire de Poitiers, Huntsman Cancer Institute, Jena University Hospital, South Australia Pathology, South Australian Health and Medical Research Institute, The University of Adelaide, University of California, San Francisco
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2597786462